Recombinant acellular pertussis vaccine - BioNet-Asia

Drug Profile

Recombinant acellular pertussis vaccine - BioNet-Asia

Alternative Names: rPT vaccine; Viaskin® rPT; Viaskin®-PT

Latest Information Update: 01 Feb 2017

Price : $50

At a glance

  • Originator BioNet-Asia; Mahidol University
  • Developer BioNet-Asia; DBV Technologies; University of Geneva
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Registered Pertussis

Most Recent Events

  • 23 Dec 2016 Registered for Pertussis (Prevention) in Thailand (IM)
  • 06 Sep 2016 Phase-I clinical trials in Pertussis (Prevention) in Switzerland (Transdermal)
  • 31 Aug 2016 Phase-III clinical trials in Pertussis (Prevention) in Thailand (IM) before August 2016 (BioNet-Asia pipeline, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top